Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Change in Cash: 2017-2025

Historic Change in Cash for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$216.9 million.

  • Cidara Therapeutics' Change in Cash fell 486.55% to -$216.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.6 million, marking a year-over-year increase of 119.27%. This contributed to the annual value of $160.4 million for FY2024, which is 5164.16% up from last year.
  • As of Q3 2025, Cidara Therapeutics' Change in Cash stood at -$216.9 million, which was down 163.35% from $342.4 million recorded in Q2 2025.
  • Over the past 5 years, Cidara Therapeutics' Change in Cash peaked at $342.4 million during Q2 2025, and registered a low of -$216.9 million during Q3 2025.
  • Its 3-year average for Change in Cash is $24.3 million, with a median of -$1.8 million in 2023.
  • The largest annual percentage gain for Cidara Therapeutics' Change in Cash in the last 5 years was 5,415.53% (2024), contrasted with its biggest fall of 2,001.31% (2024).
  • Cidara Therapeutics' Change in Cash (Quarterly) stood at $22.0 million in 2021, then slumped by 192.62% to -$20.3 million in 2022, then surged by 36.64% to -$12.9 million in 2023, then surged by 633.59% to $68.8 million in 2024, then plummeted by 486.55% to -$216.9 million in 2025.
  • Its last three reported values are -$216.9 million in Q3 2025, $342.4 million for Q2 2025, and -$21.7 million during Q1 2025.